Treatment With Local PPARgamma Ligand in Distal Ulcerative Colitis

• Status: Unknown status
• Trial end date: 2007-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Treatment with PPARgamma ligands have been shown to reduces intestinal inflammation in murine models of colitis. The aim of this study was to evaluate the effect of treatment with local PPARgamma ligand (rosiglitazone) in distal ulcerative colitis.The patients are treated with rosiglitazone enema, once a day, for fourteen days. Disease activity was assessed before and after treatment by endoscopical and clinical activity score.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Herlev Hospital
• Treatments: Rosiglitazone

Criteria

Inclusion Criteria:

• Distal ulcerative colitis (Mayo Clinical Score > 7)

• Age > 18 years

• Written consent

Exclusion Criteria:

• Age < 18 years

• Severe ulcerative colitis

• Systemic treatment with steroids or azathioprin within the last 3 month

• Known liver or kidney disease

• Severe heart failure

• Pregnancy or breast feeding